S1PR4 and metabolic dysfunction-associated steatohepatitis: Moreover, the potential of NXC736 has been examined in lung fibrosis [15] and as a pharmacological tool to elucidate the role of S1P4 in metabolic dysfunction-associated steatohepatitis (MASH) [14] and transient ischemic stroke [13].